Hydroxyethyl starch-induced pruritus: Clinical characteristics and influence of dose, molecular weight and substitution

Acta Dermato-Venereologica

Volumn 94, Issue 3, 2014, Pages 282-287

  Ständer, Sonja ^a   Richter, Laura ^a   Osada, Nani ^a   Metze, Dieter ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Dose; Hydroxyethyl starch; Molar substitution; Molecular weight; Pruritus; Tissue storage

Indexed keywords

HETASTARCH; HETASTARCH DERIVATIVE; PLASMA SUBSTITUTE;

ADULT; AGED; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EXPOSURE; ELECTRON MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MECHANICAL STIMULATION; MOLECULAR WEIGHT; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SKIN CELL; CHEMICALLY INDUCED; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SKIN; TIME; ULTRASTRUCTURE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MOLECULAR WEIGHT; PLASMA SUBSTITUTES; PRURITUS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS;

EID: 84899908144     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1639     Document Type: Article

References (44)

1. Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, et al. Resuscitation fluid use in critically ill adults: an international cross sectional study in 391 intensive care units. Crit Care 2010; 14: R185.
2. Bellmann R, Feistritzer C, Wiedermann CJ. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clin Pharmacokinet 2012; 51: 225-236.
3. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997; 136: 553-559.
4. Reimann S, Szépfalusi Z, Kraft D, Luger T, Metze D. Hydroxyethylstärke-Speicherung in der Haut unter besonderer Berücksichtigung des Hydroxyethylstärke-assoziierten Juckreizes. Dtsch Med Wochenschr 2000; 125: 280-285.
5. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth 1999; 82: 510-515.
6. Ständer S, Szépfalusi Z, Bohle B, Ständer H, Kraft D, Luger TA, et al. Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical long-term study. Cell Tissue Res 2001; 304: 261-269.
7. Bork K. Pruritus precipitated by hydroxyethyl starch: a review. Br J Dermatol 2005; 152: 3-12.
8. Grundmann T, Gramer L. Pruritus bei Infusionstherapie mit Hydroxyethylstärke verschiedener Menge. Wehrmed Mschr 1993; 2: 47-48.
9. Desloovere C, Knecht R. Infusionstherapie bei Hörsturz: Reduktion des Juckreizrisikos nach Hydroxyethylstärke (HES) unter Erhalt des Therapieerfolges - eine prospektive randomisierte Studie. Laryngorhinootologie 1995; 74: 468-472.
10. Gall H, Kaufmann R, von Ehr M, Schumann K, Sterry W. Persistierender Pruritus nach Hydroxyäthylstärke-Infusionen: retrospektive Langzeitstudie an 266 Fällen. Hautarzt 1993; 44: 713-716.
11. Leunig A, Szeimies RM, Wilmes E, Gutmann R, Stolz W, Feyh J. Klinische und elektronenmikroskopische Untersuchung zur Hörsturztherapie mit der Kombination 10% HES 200/0,5 und Pentoxifyllin. Laryngorhinootologie 1995; 74: 135-140.
12. Kimme P, Jannsen B, Ledin T, Gupta A, Vegfors M. High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions. Acta Anaesthesiol Scand 2001; 45: 686-689.
13. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004; 139: 552-563.
14. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products - different effects. Anesthesiology 2009; 111: 187-202.
15. Fluids Study Investigators for the Scandinavian Critical Care Trials Group. Preferences for colloid use in Scandinavian intensive care units. Acta Anaesthesiol Scand 2008; 52: 750-758.
16. Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg 2011; 112: 635-645.
17. Ständer S. Chronischer Pruritus: Prinzipien der Diagnostik und Therapie. Hautarzt 2007; 58: 627-636.
18. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.
19. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501.
20. Bode U, Deisseroth AB. Donor toxicity in granulocyte collections: association of lichen planus with the use of hydroxyethyl starch leukapheresis. Transfusion 1981; 21: 83-85.
21. Parker NE, Porter JB, Williams HJ, Leftley N. Pruritus after administration of hetastarch. Br Med J (Clin Res Ed) 1982; 284: 385-386.
22. Bux J, Cassens U, Dielschneider T, Duchscherer M, Edel E, Eichler H, et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang 2003; 85: 322-325.
23. Albegger K, Schneeberger R, Franke V, Oberascher G, Miller K. Juckreiz nach Therapie mit Hydroxyäthylstärke (HES) bei otoneurologischen Erkrankungen. Wien Med Wochenschr 1992; 142: 1-7.
24. Speight EL, MacSween RM, Stevens A. Persistent itching due to etherified starch plasma expander. BMJ 1997; 314: 1466-1467.
25. Sharland C, Huggett A, Nielson MS, Friedmann PS. Persistent pruritus after pentastarch infusions in intensive care patients. Anaesthesia 1999; 54: 500-501.
26. Morgan PW, Berridge JC. Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery. Br J Anaesth 2000; 85: 696-699.
27. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005; 5: 1120-1129.
28. Cox NH, Popple AW. Persistent erythema and pruritus, with a confluent histiocytic skin infiltrate, following the use of a hydroxyethylstarch plasma expander. Br J Dermatol 1996; 134: 353-357.
29. Gall H, Schultz KD, Boehncke WH, Kaufmann R. Clinical and pathophysiological aspects of hydroxyethyl starchinduced pruritus: evaluation of 96 cases. Dermatology 1996; 192: 222-226.
30. Ständer S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol 2003; 139: 1463-1470.
31. Ständer S, Evers S, Metze D, Schmelz M. Neurophysiological evidence for altered sensory function caused by storage of hydroxyethyl starch in cutaneous nerve fibres. Br J Dermatol 2005; 152: 1085-1086.
32. Ringkamp M, Schepers RJ, Shimada SG, Johanek LM, Hartke TV, Borzan J, et al. A role for nociceptive, myelinated nerve fibers in itch sensation. J Neurosci 2011; 31: 14841-14849.
33. Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M. Separate peripheral pathways for pruritus in man. J Neurophysiol 2008; 100: 2062-2069.
34. Kosteletzky F, Namer B, Forster C, Handwerker HO. Impact of scratching on itch and sympathetic reflexes induced by cowhage (Mucuna pruriens) and histamine. Acta Derm Venereol 2009; 89: 271-277.
35. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901-1911.
36. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 versus 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012; 16: R94.
37. Patel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 2013; 39: 811-822.
38. Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 2012; 38: 368-383.
39. Lukasewitz P, Kroh U, Löwenstein O, Krämer M, Lennartz H. Quantitative Untersuchungen zur Gewebsspeicherung von mittelmolekularer Hydroxyethylstärke 200/0,5 bei Patienten mit Multiorganversagen. J Anaesth Intensivbeh 1998; 3: 42-46.
40. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620-1622.
41. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013; 39: 558-568.
42. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38- 0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013; 346: 839.
43. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309: 678-688.
44. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013; 41: 580-637.